LBTYA

SEC source: 0001570585-21-000154 · wf-form4_162016471285991.xml · nonDerivative · entry 1

HALL BRYAN H · CIK 0001292152 · EVP, Gen Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,588

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

SEC source: 0001570585-21-000155 · wf-form4_162016473779354.xml · derivative · entry 7

Rodriguez Enrique · CIK 0001565787 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,210

Underlying: Class C Ordinary Shares · 41,104 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F3 · derivative.exercise_date: The RSUs vest in three equal annual installments commencing on May 1, 2021.

F3 · derivative.expiration_date: The RSUs vest in three equal annual installments commencing on May 1, 2021.

SEC source: 0001570585-21-000155 · wf-form4_162016473779354.xml · derivative · entry 6

Rodriguez Enrique · CIK 0001565787 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,105

Underlying: Class A Ordinary Shares · 20,552 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F3 · derivative.exercise_date: The RSUs vest in three equal annual installments commencing on May 1, 2021.

F3 · derivative.expiration_date: The RSUs vest in three equal annual installments commencing on May 1, 2021.

SEC source: 0001570585-21-000155 · wf-form4_162016473779354.xml · nonDerivative · entry 4

Rodriguez Enrique · CIK 0001565787 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 177,253

SEC source: 0001570585-21-000155 · wf-form4_162016473779354.xml · nonDerivative · entry 3

Rodriguez Enrique · CIK 0001565787 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,764

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

SEC source: 0001570585-21-000155 · wf-form4_162016473779354.xml · nonDerivative · entry 2

Rodriguez Enrique · CIK 0001565787 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,615

SEC source: 0001570585-21-000155 · wf-form4_162016473779354.xml · nonDerivative · entry 1

Rodriguez Enrique · CIK 0001565787 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,871

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

SEC source: 0001570585-21-000156 · wf-form4_162016476286321.xml · derivative · entry 6

Salvato Andrea · CIK 0001778743 · SVP, CHIEF DEVELOPMENT OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,767

Underlying: Class C Ordinary Shares · 32,883 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F2 · derivative.exercise_date: The RSUs vest in three equal annual installments commencing on May 1, 2021.

F2 · derivative.expiration_date: The RSUs vest in three equal annual installments commencing on May 1, 2021.

SEC source: 0001570585-21-000156 · wf-form4_162016476286321.xml · derivative · entry 5

Salvato Andrea · CIK 0001778743 · SVP, CHIEF DEVELOPMENT OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,884

Underlying: Class A Ordinary Shares · 16,441 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F2 · derivative.exercise_date: The RSUs vest in three equal annual installments commencing on May 1, 2021.

F2 · derivative.expiration_date: The RSUs vest in three equal annual installments commencing on May 1, 2021.

SEC source: 0001570585-21-000156 · wf-form4_162016476286321.xml · nonDerivative · entry 4

Salvato Andrea · CIK 0001778743 · SVP, CHIEF DEVELOPMENT OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,964

SEC source: 0001570585-21-000156 · wf-form4_162016476286321.xml · nonDerivative · entry 3

Salvato Andrea · CIK 0001778743 · SVP, CHIEF DEVELOPMENT OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,420

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

SEC source: 0001570585-21-000156 · wf-form4_162016476286321.xml · nonDerivative · entry 2

Salvato Andrea · CIK 0001778743 · SVP, CHIEF DEVELOPMENT OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,611

SEC source: 0001570585-21-000156 · wf-form4_162016476286321.xml · nonDerivative · entry 1

Salvato Andrea · CIK 0001778743 · SVP, CHIEF DEVELOPMENT OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,339

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

SEC source: 0001570585-21-000119 · wf-form4_161852239913131.xml · derivative · entry 8

GOULD PAUL A · CIK 0001018211 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,548

Underlying: Class C Ordinary Shares · 8,548 shares

Expires 2025-06-25

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable.

SEC source: 0001570585-21-000119 · wf-form4_161852239913131.xml · derivative · entry 7

GOULD PAUL A · CIK 0001018211 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class C Ordinary Shares · 8,548 shares

Expires 2022-06-25

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable.

SEC source: 0001570585-21-000119 · wf-form4_161852239913131.xml · derivative · entry 6

GOULD PAUL A · CIK 0001018211 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,303

Underlying: Class A Ordinary Shares · 4,303 shares

Expires 2025-06-25

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable.

SEC source: 0001570585-21-000119 · wf-form4_161852239913131.xml · derivative · entry 5

GOULD PAUL A · CIK 0001018211 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 4,303 shares

Expires 2022-06-25

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable.

SEC source: 0001570585-21-000119 · wf-form4_161852239913131.xml · derivative · entry 4

GOULD PAUL A · CIK 0001018211 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,379

Underlying: Class C Ordinary Shares · 11,379 shares

Expires 2024-06-26

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable.

SEC source: 0001570585-21-000119 · wf-form4_161852239913131.xml · derivative · entry 3

GOULD PAUL A · CIK 0001018211 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class C Ordinary Shares · 11,379 shares

Expires 2021-06-26

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable.

SEC source: 0001570585-21-000119 · wf-form4_161852239913131.xml · derivative · entry 2

GOULD PAUL A · CIK 0001018211 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,716

Underlying: Class A Ordinary Shares · 5,716 shares

Expires 2024-06-26

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable.

SEC source: 0001570585-21-000119 · wf-form4_161852239913131.xml · derivative · entry 1

GOULD PAUL A · CIK 0001018211 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 5,716 shares

Expires 2021-06-26

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable.

SEC source: 0001570585-21-000121 · wf-form4_161852256683584.xml · derivative · entry 12

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,606

Underlying: Class C Ordinary Shares · 105,606 shares

Expires 2025-05-01

F4 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F4 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F4 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F5 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable.

SEC source: 0001570585-21-000121 · wf-form4_161852256683584.xml · derivative · entry 11

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class C Ordinary Shares · 105,606 shares

Expires 2022-05-01

F4 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F4 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F4 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F5 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable.

SEC source: 0001570585-21-000121 · wf-form4_161852256683584.xml · derivative · entry 10

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,376

Underlying: Class A Ordinary Shares · 52,376 shares

Expires 2025-05-01

F4 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F4 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F4 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F5 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable.

SEC source: 0001570585-21-000121 · wf-form4_161852256683584.xml · derivative · entry 9

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 52,376 shares

Expires 2022-05-01

F4 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F4 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F4 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F5 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable.

SEC source: 0001570585-21-000121 · wf-form4_161852256683584.xml · derivative · entry 8

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,804

Underlying: Class C Ordinary Shares · 133,804 shares

Expires 2024-05-01

F4 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F4 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F4 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F5 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable.

SEC source: 0001570585-21-000121 · wf-form4_161852256683584.xml · derivative · entry 7

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class C Ordinary Shares · 133,804 shares

Expires 2021-05-01

F4 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F4 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F4 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F5 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable.

SEC source: 0001570585-21-000121 · wf-form4_161852256683584.xml · derivative · entry 6

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,243

Underlying: Class A Ordinary Shares · 67,243 shares

Expires 2024-05-01

F4 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F4 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F4 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F5 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable.

SEC source: 0001570585-21-000121 · wf-form4_161852256683584.xml · derivative · entry 5

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 67,243 shares

Expires 2021-05-01

F4 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F4 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F4 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F5 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable.

SEC source: 0001570585-21-000121 · wf-form4_161852256683584.xml · derivative · entry 4

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 767,122

Underlying: Class C Ordinary Shares · 767,122 shares

Expires 2031-04-13

F3 · derivative.exercise_date: The Share Appreciation Rights vest 50% on May 1, 2023 and 50% on May 1, 2024.

SEC source: 0001570585-21-000121 · wf-form4_161852256683584.xml · derivative · entry 3

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 383,561

Underlying: Class A Ordinary Shares · 383,561 shares

Expires 2031-04-13

F3 · derivative.exercise_date: The Share Appreciation Rights vest 50% on May 1, 2023 and 50% on May 1, 2024.

SEC source: 0001570585-21-000121 · wf-form4_161852256683584.xml · derivative · entry 2

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,066

Underlying: Class C Ordinary Shares · 84,066 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F2 · derivative.exercise_date: The RSUs vest in three equal annual installments commencing on May 1, 2022.

F2 · derivative.expiration_date: The RSUs vest in three equal annual installments commencing on May 1, 2022.

SEC source: 0001570585-21-000121 · wf-form4_161852256683584.xml · derivative · entry 1

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,033

Underlying: Class A Ordinary Shares · 42,033 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F2 · derivative.exercise_date: The RSUs vest in three equal annual installments commencing on May 1, 2022.

F2 · derivative.expiration_date: The RSUs vest in three equal annual installments commencing on May 1, 2022.

SEC source: 0001570585-21-000118 · wf-form4_161852228183958.xml · derivative · entry 8

WARGO J DAVID · CIK 0001082013 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,548

Underlying: Class C Ordinary Shares · 8,548 shares

Expires 2025-06-25

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable.

SEC source: 0001570585-21-000118 · wf-form4_161852228183958.xml · derivative · entry 7

WARGO J DAVID · CIK 0001082013 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class C Ordinary Shares · 8,548 shares

Expires 2022-06-25

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable.

SEC source: 0001570585-21-000118 · wf-form4_161852228183958.xml · derivative · entry 6

WARGO J DAVID · CIK 0001082013 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,303

Underlying: Class A Ordinary Shares · 4,303 shares

Expires 2025-06-25

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable.

SEC source: 0001570585-21-000118 · wf-form4_161852228183958.xml · derivative · entry 5

WARGO J DAVID · CIK 0001082013 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 4,303 shares

Expires 2022-06-25

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable.

SEC source: 0001570585-21-000118 · wf-form4_161852228183958.xml · derivative · entry 4

WARGO J DAVID · CIK 0001082013 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,379

Underlying: Class C Ordinary Shares · 11,379 shares

Expires 2024-06-26

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable.

SEC source: 0001570585-21-000118 · wf-form4_161852228183958.xml · derivative · entry 3

WARGO J DAVID · CIK 0001082013 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class C Ordinary Shares · 11,379 shares

Expires 2021-06-26

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable.

SEC source: 0001570585-21-000118 · wf-form4_161852228183958.xml · derivative · entry 2

WARGO J DAVID · CIK 0001082013 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,716

Underlying: Class A Ordinary Shares · 5,716 shares

Expires 2024-06-26

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable.

SEC source: 0001570585-21-000118 · wf-form4_161852228183958.xml · derivative · entry 1

WARGO J DAVID · CIK 0001082013 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 5,716 shares

Expires 2021-06-26

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable.

SEC source: 0001570585-21-000126 · wf-form4_161852289568221.xml · derivative · entry 9

FRIES MICHAEL T · CIK 0001058725 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 316,802

Underlying: Class C Ordinary Shares · 316,802 shares

Expires 2025-05-01

F2 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F3 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable.

SEC source: 0001570585-21-000126 · wf-form4_161852289568221.xml · derivative · entry 8

FRIES MICHAEL T · CIK 0001058725 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class C Ordinary Shares · 316,802 shares

Expires 2022-05-01

F2 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F3 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable.

SEC source: 0001570585-21-000126 · wf-form4_161852289568221.xml · derivative · entry 7

FRIES MICHAEL T · CIK 0001058725 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,121

Underlying: Class A Ordinary Shares · 157,121 shares

Expires 2025-05-01

F2 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F3 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable.

SEC source: 0001570585-21-000126 · wf-form4_161852289568221.xml · derivative · entry 6

FRIES MICHAEL T · CIK 0001058725 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 157,121 shares

Expires 2022-05-01

F2 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F3 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable.

SEC source: 0001570585-21-000126 · wf-form4_161852289568221.xml · derivative · entry 5

FRIES MICHAEL T · CIK 0001058725 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 401,446

Underlying: Class C Ordinary Shares · 401,446 shares

Expires 2024-05-01

F2 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F3 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable.

SEC source: 0001570585-21-000126 · wf-form4_161852289568221.xml · derivative · entry 4

FRIES MICHAEL T · CIK 0001058725 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class C Ordinary Shares · 401,446 shares

Expires 2021-05-01

F2 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F3 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable.

SEC source: 0001570585-21-000126 · wf-form4_161852289568221.xml · derivative · entry 3

FRIES MICHAEL T · CIK 0001058725 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 201,746

Underlying: Class A Ordinary Shares · 201,746 shares

Expires 2024-05-01

F2 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F3 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable.

SEC source: 0001570585-21-000126 · wf-form4_161852289568221.xml · derivative · entry 2

FRIES MICHAEL T · CIK 0001058725 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 201,746 shares

Expires 2021-05-01

F2 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F3 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable.

SEC source: 0001570585-21-000126 · wf-form4_161852289568221.xml · derivative · entry 1

FRIES MICHAEL T · CIK 0001058725 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,378,211

Underlying: Class C Ordinary Shares · 5,378,211 shares

Expires 2031-04-13

F1 · derivative.exercise_date: The Share Appreciation Rights vest 50% on May 1, 2023 and 50% on May 1, 2024.